Improved specific activity of reactor produced 117mSn with the Szilard-Chalmers process

https://doi.org/10.1016/0883-2889(92)90053-HGet rights and content

Abstract

We report an investigation of the application of the Szilard-Chalmers process to improve the specific activity of reactor produced 117mSn. The radiopharmaceutical 117mSn4+DTPA is a promising agent for relieving bone pain in breast and prostate cancer patients. Preliminary studies in these patients have given very encouraging results. For this application high specific activity 117mSn is required to minimize the quantity of administered DTPA. Using a tetraphenyltin target we have investigated solvent extraction and ion exchange techniques to enrich the radioactive atom concentration. Other variables studied include the effect of neutron flux, total neutron fluence and sample mass. The enrichment factor was comparable for both solvent extraction and ion exchange techniques, but solvent extraction was more convenient. For 1 h irradiations the enrichment factor averaged ∼ 70 but declined to ∼ 2 after 24 h irradiation due to accumulated radiation damage. The enrichment factor also declined with increasing neutron energy. An isotope effect on the Szilard-Chalmers process was observed as the enrichment factor for 113Sn was consistently higher than for 117mSn.

References (14)

There are more references available in the full text version of this article.

Cited by (12)

  • The atomic nucleus, nuclear radiation, and the interaction of radiation with matter

    2020, Handbook of Radioactivity Analysis: Volume 1: Radiation Physics and Detectors
  • Radiation Physics and Radionuclide Decay

    2012, Handbook of Radioactivity Analysis
  • Radioactivity: History, Science, Vital Uses and Ominous Peril

    2022, Radioactivity: History, Science, Vital Uses and Ominous Peril
  • Radioactivity: Introduction and History, From the Quantum to Quarks: Second Edition

    2016, Radioactivity: Introduction and History, From the Quantum to Quarks: Second Edition
  • Radiopharmaceuticals for therapy

    2016, Radiopharmaceuticals for Therapy
View all citing articles on Scopus

Now at Nuclear Medicine Group, Oak Ridge National Laboratory, Oak Ridge, TN 37831-6022, U.S.A.

View full text